Omalizumab (Xolair) in Children Above 12 Years With Chronic Urticaria: A Review of Literature
Generally, 15-25% of general population experience urticaria during their life. The prevalence of chronic urticaria is about 0.1-0.3% in children and most often occurs between ages of 6-11 years. There are several causes for development of chronic urticaria. Known etiologies of chronic urticaria in...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mazandaran University of Medical Sciences
2015-01-01
|
| Series: | Journal of Pediatrics Review |
| Subjects: | |
| Online Access: | http://jpr.mazums.ac.ir/browse.php?a_code=A-10-28-8&slc_lang=en&sid=1 |
| _version_ | 1818309272751046656 |
|---|---|
| author | Javad Ghaffari Soheila Shahmohammadi Hossein Ashrafi Ali Reza Ranjbar Negar Ghaffari |
| author_facet | Javad Ghaffari Soheila Shahmohammadi Hossein Ashrafi Ali Reza Ranjbar Negar Ghaffari |
| author_sort | Javad Ghaffari |
| collection | DOAJ |
| description | Generally, 15-25% of general population experience urticaria during their life. The prevalence of chronic urticaria is about 0.1-0.3% in children and most often occurs between ages of 6-11 years. There are several causes for development of chronic urticaria. Known etiologies of chronic urticaria in children vary from 21% to 83%. Chronic urticaria caused by infections is more common in children than adults. Diagnosis of chronic urticaria is based on clinical history and physical examination and routine laboratory testing in the absence of a clinical history is rarely helpful. Similar to adults, antihistamines are the first line of treatment. Omalizumab as a biological engineering molecule is a recombinant humanized monoclonal antibody, which targets the CH3 domain of the ε chain of the free IgE. Omalizumab has been used in patients with H1-antihistamine-refractory chronic idiopathic urticaria (CIU). Here in we made a review about possible mechanisms by which omalizumab may be effective in children above 12 years with chronic urticaria, and also focused on its therapeutic effects, onset criteria and possible side effects. |
| first_indexed | 2024-12-13T07:27:32Z |
| format | Article |
| id | doaj.art-7998d9f8d5b049b392f34e8cbf9674f0 |
| institution | Directory Open Access Journal |
| issn | 2322-4398 2322-4401 |
| language | English |
| last_indexed | 2024-12-13T07:27:32Z |
| publishDate | 2015-01-01 |
| publisher | Mazandaran University of Medical Sciences |
| record_format | Article |
| series | Journal of Pediatrics Review |
| spelling | doaj.art-7998d9f8d5b049b392f34e8cbf9674f02022-12-21T23:55:17ZengMazandaran University of Medical SciencesJournal of Pediatrics Review2322-43982322-44012015-01-013100Omalizumab (Xolair) in Children Above 12 Years With Chronic Urticaria: A Review of LiteratureJavad Ghaffari0Soheila Shahmohammadi1Hossein Ashrafi2Ali Reza Ranjbar3Negar Ghaffari4 Antimicrobial Resistant Nosocomial Infection Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran Antimicrobial Resistant Nosocomial Infection Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran Beatson Institute for Cancer Research, Faculty of Medicine, University of Glasgow, Glasgow, UK Research Institute of Interventional Allergology and Immunology, Bonn, Germany Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran Generally, 15-25% of general population experience urticaria during their life. The prevalence of chronic urticaria is about 0.1-0.3% in children and most often occurs between ages of 6-11 years. There are several causes for development of chronic urticaria. Known etiologies of chronic urticaria in children vary from 21% to 83%. Chronic urticaria caused by infections is more common in children than adults. Diagnosis of chronic urticaria is based on clinical history and physical examination and routine laboratory testing in the absence of a clinical history is rarely helpful. Similar to adults, antihistamines are the first line of treatment. Omalizumab as a biological engineering molecule is a recombinant humanized monoclonal antibody, which targets the CH3 domain of the ε chain of the free IgE. Omalizumab has been used in patients with H1-antihistamine-refractory chronic idiopathic urticaria (CIU). Here in we made a review about possible mechanisms by which omalizumab may be effective in children above 12 years with chronic urticaria, and also focused on its therapeutic effects, onset criteria and possible side effects.http://jpr.mazums.ac.ir/browse.php?a_code=A-10-28-8&slc_lang=en&sid=1OmalizumabChronic UrticariaChildTherapeutics |
| spellingShingle | Javad Ghaffari Soheila Shahmohammadi Hossein Ashrafi Ali Reza Ranjbar Negar Ghaffari Omalizumab (Xolair) in Children Above 12 Years With Chronic Urticaria: A Review of Literature Journal of Pediatrics Review Omalizumab Chronic Urticaria Child Therapeutics |
| title | Omalizumab (Xolair) in Children Above 12 Years With Chronic Urticaria: A Review of Literature |
| title_full | Omalizumab (Xolair) in Children Above 12 Years With Chronic Urticaria: A Review of Literature |
| title_fullStr | Omalizumab (Xolair) in Children Above 12 Years With Chronic Urticaria: A Review of Literature |
| title_full_unstemmed | Omalizumab (Xolair) in Children Above 12 Years With Chronic Urticaria: A Review of Literature |
| title_short | Omalizumab (Xolair) in Children Above 12 Years With Chronic Urticaria: A Review of Literature |
| title_sort | omalizumab xolair in children above 12 years with chronic urticaria a review of literature |
| topic | Omalizumab Chronic Urticaria Child Therapeutics |
| url | http://jpr.mazums.ac.ir/browse.php?a_code=A-10-28-8&slc_lang=en&sid=1 |
| work_keys_str_mv | AT javadghaffari omalizumabxolairinchildrenabove12yearswithchronicurticariaareviewofliterature AT soheilashahmohammadi omalizumabxolairinchildrenabove12yearswithchronicurticariaareviewofliterature AT hosseinashrafi omalizumabxolairinchildrenabove12yearswithchronicurticariaareviewofliterature AT alirezaranjbar omalizumabxolairinchildrenabove12yearswithchronicurticariaareviewofliterature AT negarghaffari omalizumabxolairinchildrenabove12yearswithchronicurticariaareviewofliterature |